4.7 Article

Time to remission in swollen joints is far faster than patient reported outcomes in rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI)

期刊

RHEUMATOLOGY
卷 60, 期 2, 页码 717-727

出版社

OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keaa343

关键词

rheumatoid arthritis; outcome measures; patient-reported outcomes; CDAI; remission; LDA; fatigue

资金

  1. CIHR (Canadian Institute for Health Research)
  2. Ontario Ministry of Health and Long-Term Care (MOHLTC)
  3. Canadian Arthritis Network (CAN)
  4. Abbvie
  5. Amgen
  6. Celgene
  7. Hospira
  8. Janssen
  9. Lilly
  10. Merck
  11. Novartis
  12. Pfizer
  13. Roche
  14. Sanofi
  15. UCB

向作者/读者索取更多资源

The study found that the time to achieve remission in rheumatoid arthritis patients based on patient-reported outcomes is longer compared to swollen joint count. Early RA patients generally reach low disease state or remission faster than established RA patients, with fatigue being an exception.
Objectives RA patients are often not in remission due to patient global assessment of disease activity (PtGA) included in disease activity indices. The aim was to assess the lag of patient-reported outcomes (PROs) after remission measured by clinical disease activity index (CDAI) or swollen joint count (SJC28). Methods RA patients enrolled in the Ontario Best Practices Research Initiative registry not in low disease state at baseline with at >= 6 months of follow-up, were included. Low disease state was defined as CDAI <= 10, SJC28 <= 2, PtGA <= 2cm, pain score <= 2cm, or fatigue <= 2cm. Remission included CDAI <= 2.8, SJC28 <= 1, PtGA <= 1cm, pain score <= 1cm, or fatigue <= 1cm. Time to first low disease state/remission based on each definition was calculated overall and stratified by early vs established RA. Results A total of 986 patients were included (age 57.4 (12.9), disease duration 8.3 (9.9) years, 80% women). The median (95% CI) time in months to CDAI <= 10 was 12.4 (11.4, 13.6), SJC28 <= 2 was 9 (8.2, 10), PtGA <= 2cm was 18.9 (16.1, 22), pain <= 2cm was 24.5 (19.4, 30.5), and fatigue <= 2cm was 30.4 (24.8, 31.7). For remission, the median (95% CI) time in months to CDAI <= 2.8 was 46.5 (42, 54.1), SJC28 <= 1 was 12.5 (11.4, 13.4), PtGA <= 1cm was 39.6 (34.6, 44.8), pain <= 1cm was 54.7 (43.6, 57.5) and fatigue <= 1cm was 42.6 (36.8, 48). Time to achieving low disease state and remission was generally significantly shorter in early RA compared with established RA with the exception of fatigue. Conclusion Time to achieving low disease state or remission based on PROs was considerably longer compared with swollen joint count. Treating to a composite target in RA could lead to inappropriate changes in DMARDs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据